SEC Form 4 · accession 0000891293-15-000053
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Oct 5, 2015
Accepted (ET)
Oct 7, 2015 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 5, 2015 | S | 1,400 | $1.515 | D | 648,684 | D | |
| Common Stock | Oct 5, 2015 | S | 6,916 | $1.52 | D | 641,768 | D | |
| Common Stock | Oct 5, 2015 | S | 1,100 | $1.525 | D | 640,668 | D | |
| Common Stock | Oct 5, 2015 | S | 584 | $1.53 | D | 640,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan.